Spread the news

Patient Care Technician Fanta Keita treats a Covid-19 positive patient, as she lays on the emergency room bed at Roseland Community Hospital on the South Side of Chicago, Illinois December 2, 2020. — Reuters pic
Patient Care Technician Fanta Keita treats a Covid-19 positive patient, as she lays on the emergency room bed at Roseland Community Hospital on the South Side of Chicago, Illinois December 2, 2020. — Reuters pic

Follow us on Instagram and subscribe to our Telegram channel for the latest updates.


WASHINGTON, Sept 9 ― The US Food and Drug Administration declined Humanigen Inc’s request for emergency use authorisation (EUA) of its lenzilumab drug to treat newly hospitalised Covid-19 patients, the company said today.

“In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for Covid-19,” the company said in a statement.

Humanigen expects an ongoing study to provide additional safety and efficacy data to support its new EUA request.

The company filed its application with the FDA for emergency use of the drug in May, citing late-stage trial data.

Humanigen also started the process of UK authorisation for the drug in June through a rolling review submission. ― Reuters

Click to rate this post!
[Total: 0 Average: 0]

Spread the news
CONTACT US : support@melodyinter.com
Previous articleNear-Bangkok cafe rolls out red carpet to pay homage to the cinema age
Next articleChelsea Fined By FA Over Liverpool Protests

LEAVE A REPLY

Please enter your comment!
Please enter your name here